docosahexaenoate and Fatty-Liver

docosahexaenoate has been researched along with Fatty-Liver* in 1 studies

Other Studies

1 other study(ies) available for docosahexaenoate and Fatty-Liver

ArticleYear
Design, Synthesis, and Preclinical Efficacy of Novel Nonretinoid Antagonists of Retinol-Binding Protein 4 in the Mouse Model of Hepatic Steatosis.
    Journal of medicinal chemistry, 2019, 06-13, Volume: 62, Issue:11

    Retinol-binding protein 4 (RBP4) serves as a transporter for all- trans-retinol (1) in the blood, and it has been proposed to act as an adipokine. Elevated plasma levels of the protein have been linked to diabetes, obesity, cardiovascular diseases, and nonalcoholic fatty liver disease (NAFLD). Recently, adipocyte-specific overexpression of RBP4 was reported to cause hepatic steatosis in mice. We previously identified an orally bioavailable RBP4 antagonist that significantly lowered RBP4 serum levels in Abca4

    Topics: Animals; Chemistry Techniques, Synthetic; Disease Models, Animal; Drug Design; Fatty Liver; Male; Mice; Piperidines; Rats; Retinol-Binding Proteins, Plasma; Tissue Distribution

2019